Filing Details

Accession Number:
0001140361-18-031061
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-07-02 21:08:03
Reporting Period:
2018-07-02
Accepted Time:
2018-07-02 21:08:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595585 Tricida Inc. TCDA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1572451 P David Bonita 7000 Shoreline Court, Suite 201
South San Francisco CA 94080
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-07-02 1,559,716 $0.00 1,559,716 No 4 C Indirect By OrbiMed Private Investments V, LP
Common Stock Acquisiton 2018-07-02 4,300,774 $0.00 5,860,490 No 4 C Indirect By OrbiMed Private Investments V, LP
Common Stock Acquisiton 2018-07-02 3,591,194 $0.00 9,451,684 No 4 C Indirect By OrbiMed Private Investments V, LP
Common Stock Acquisiton 2018-07-02 1,069,175 $0.00 10,520,859 No 4 C Indirect By OrbiMed Private Investments V, LP
Common Stock Acquisiton 2018-07-02 368,421 $19.00 10,889,280 No 4 P Indirect By OrbiMed Private Investments V, LP
Common Stock Acquisiton 2018-07-02 3,632 $0.00 3,632 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By OrbiMed Private Investments V, LP
No 4 C Indirect By OrbiMed Private Investments V, LP
No 4 C Indirect By OrbiMed Private Investments V, LP
No 4 C Indirect By OrbiMed Private Investments V, LP
No 4 P Indirect By OrbiMed Private Investments V, LP
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2018-07-02 6,207,674 $0.00 1,559,716 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2018-07-02 17,117,085 $0.00 4,300,774 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2018-07-02 14,292,958 $0.00 3,591,194 $0.00
Common Stock Series D Convertible Preferred Stock Disposition 2018-07-02 4,255,319 $0.00 1,069,175 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2018-07-02 13,147 $0.00 13,147 $19.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
13,147 2028-06-27 No 4 A Direct
Footnotes
  1. Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock.
  2. These shares are held directly by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("OrbiMed GP") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed GP. The Reporting Person is an employee of OrbiMed Advisors. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  3. Represents restricted stock units ("RSUs") that, subject to the Issuer's initial public offering ("IPO") closing on or before July 16, 2018, vest on the earlier of (i) the one-year anniversary of June 27, 2018 (the "Grant Date") and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date (the "Next Annual Meeting"), subject to the Reporting Person's continuous service as a non-employee director through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock.
  4. Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, and subject to the Issuer's IPO closing on or before July 16, 2018, this option vests ratably on a monthly basis, on the monthly anniversary of June 27, 2018 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Next Annual Meeting occurs prior to the Vesting Date, then the option shall vest in full immediately prior to the Next Annual Meeting.